DoD Parkinson's Research Program Funding Opportunities

How to Apply: 

For FY22, congress transitioned the Neurotoxin Exposure Treatment Parkinson’s (NETP) program to PRP and broadened the research from neurotoxin exposure treatment PD research to all types of PD research.  Applicants with toxic exposure research are directed to the Toxic Exposure Research Program at CDMRP.

 

The FY22 PRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

 

Applications submitted to the FY22 PRP must address one or more of the following Focus Areas:

 

  • Biological mechanisms and biomarkers of non-motor symptoms that could lead to the development of treatments for PD. Examples of non-motor symptoms of interest:

○       Cognitive dysfunction relevant to PD

○       Psychiatric dysfunction

○       Sleep and circadian rhythms disruptions

○       Autonomic dysfunction

○       Sensory dysfunction

○       Fatigue

  • Biological mechanisms and biomarkers of non-pharmacological interventions for non-motor symptoms in PD.

○       Exercise

○       Diet

○       Neuro stimulation therapy

○       Neurosurgical

○        

Funding Opportunities-FY22 PRP, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

 

Investigator-Initiated Research Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of assistant professor (or equivalent)

  • ·     Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s research.  This award mechanism supports the full spectrum of research from basic science through clinical research.
  • ·     Must address at least one of the FY22 PRP Focus Areas.
  • ·     Preliminary data to support feasibility are encouraged but not required.
  • ·     Submission of a Letter of Intent is required prior to full application submission. 
  • ·     Clinical trials are allowed.
  • ·    The maximum allowable funding for the entire period of performance is $1.2 million (M) for total costs (includes direct and indirect costs)
  • ·    The maximum period of performance is 3 years.

 

Early Investigator Research Award – Letter of Intent due August 16, 2022

Investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training completion (or equivalent).

  • ·     Supports research opportunities for investigators in the early stages of their careers and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research.
  • ·     Principal Investigators (PIs) must have at least one Mentor, who has experience in Parkinson’s disease (PD) research and mentorship.
  • ·     Must address at least one of the FY22 PRP Focus Areas.
  • ·     Preliminary data are not required but encouraged.
  • ·     Submission of a Letter of Intent is required prior to full application submission. 
  • ·     Clinical trials are not allowed.
  • ·    The maximum allowable funding for the entire period of performance is $400,000 for total costs (includes direct and indirect costs)
  • ·    The maximum period of performance is 2 years

 

Synergistic Idea Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of assistant professor (or equivalent)

  • ·     Supports new ideas that represent synergistic approaches to PD research involving two to four PIs at the assistant professor (or equivalent) level or above.
  • ·     The combined efforts of the PIs should utilize their complementary and synergistic perspectives to address a central problem or question in Parkinson’s research.
  • ·     Designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields.
  • ·     Must address at least one of the FY22 PRP Focus Areas.
  • ·     Preliminary data to support feasibility is encouraged but not required.
  • ·     Submission of a Letter of Intent is required prior to full application submission. 
  • ·     Clinical trials are allowed.
  • ·    Level 1: Maximum funding of $3.0M in total costs
  • ·    Level 2: Maximum funding of $9.0M in total costs
  • ·    The maximum period of performance is 4 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

 

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

External Deadline: 
Tuesday, August 16, 2022
URL: 

https://cdmrp.army.mil/funding/prp

Agency: 
Department of Defense
Funding Source: 
External
Funding Level: 
Research